Woolums et al. found that TRPV4-mediated neurotoxicity is regulated by the Ca2+-binding mitochondrial GTPase Miro, which demonstrates that TRPV4 antagonists are effective in the treatment of TRPV4-mediated neurodegenerative diseases (Woolums et al., 2020). Here, TRPV4 is linked to neurodegenerative disease.